Modest medical trials comparing them head-to-head at different stages of prostate cancer could be necessary. This could be carried out with asymptomatic Males who may have early Superior-stage prostate cancer (e.g. PSA > sixty ng/ml); a downward improve of PSA might be easily applied as being a appropriate biomarker endpoint in comparatively smalle